f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

New Enrollment Argus II


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Terminated
Application Number /
Requirement Number		 H110002 / PAS002
Date Original Protocol Accepted 02/13/2013
Date Current Protocol Accepted 05/13/2020
Study Name New Enrollment Argus II
Device Name ARGUS II RETINAL PROSTHESIS SYSTEM
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Device Subjects Serve as Own Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives New Enrollment Post-Approval Study: Multicenter prospective cohort study with Argus II System. Several controls are incorporated into the study. Data collected in the study will be compared with pre-implantation (Baseline) data. In addition, prospective comparisons will be made between the implant and fellow eyes, and by testing subjects visual performance with the Argus II System on and off.
Study Population Age 25 years or older; both males and females; with severe to profound retinitis pigmentosa; with bare or no light perception in both eyes or with retinal response to electrical stimulation; with previous history of useful form vision
Sample Size A total of 53 subjects will be enrolled in the study. It is anticipated that 85% of subjects will complete 5 years follow-up. This will provide a sample size of 45 subjects with complete 5 year follow-up. A minimum of 5 and a maximum of 40 centers in the US will participate in this study.
Key Study Endpoints Primary: Safety (i.e. adverse event rates), with the main safety analysis performed when all subjects have reached 2 years post-implant.
Secondary: Visual function, functional vision, and device reliability
Follow-up Visits and Length of Follow-up 5 years
Baseline, implant, month 1, 3, 6, 12, 24, 36, 48, 60.
Various follow-up assessments including medical and eye exam, functional evaluation will be tested at certain follow-up stages.
Interim or Final Data Summary
Interim Results A total of 89 device or procedure-related adverse events have been reported to date. Of these, 15 were serious and 74 non-serious. None unanticipated adverse device events reported.
Actual Number of Patients Enrolled 55 subjects
Actual Number of Sites Enrolled 19
Patient Follow-up Rate 77.4&
Study Strengths & Weaknesses This information will be included in the final report


New Enrollment Argus II Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 08/14/2013 08/14/2013 On Time
one year report 02/13/2014 02/11/2014 On Time
18 month report 08/14/2014 08/18/2014 Overdue/Received
two year report 02/13/2015 02/13/2015 On Time
three year report 02/13/2016 02/16/2016 Overdue/Received
four year report 02/12/2017 03/08/2017 Overdue/Received
five year report 02/12/2018 02/13/2018 Overdue/Received
six year report 02/12/2019 02/13/2019 Overdue/Received
seven year report 02/12/2020 02/12/2020 On Time


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-